Apogee Therapeutics, Inc. (APGE) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $82.18: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum.
Apogee Therapeutics is a clinical-stage biotech developing extended half-life antibodies for inflammatory and immunology conditions. Lead program zumilokibart (APG777, anti-IL13) completed Phase 2b Part A for atopic dermatitis with positive results and is pursuing Phase 3... Read more
Sell if holding. Engine safety override at $82.18: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: RSI 48 mid-range, Bollinger mid-band. Score 5.0/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — Apogee Therapeutics, Inc.
Latest news
- Apogee Therapeutics Q1 EPS $(1.06) Beats $(1.08) Estimate — benzinga May 11, 2026 positive
- Apogee Therapeutics Q1 2026 Net Loss $74.11M Vs. Loss Of $55.34M YoY, Cash, Cash Equivalents, Marketable Securities And — benzinga May 11, 2026 negative
- Rothschild & Co Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $140 — benzinga May 1, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinezumilokibart10-K Item 1A: 'We are substantially dependent on the success of our product candidates, zumilokibart, APG279, APG273, APG990, APG333 and APG808 and our ongoing and anticipated trials may not be successful.'
Material Events(8-K, last 90d)
- 2026-04-24Item 5.02LOWDirectors Andrew Gottesdiener, M.D. and Peter Harwin notified the Board of their intention to resign effective May 11, 2026. Board size reduced from nine to seven. No disagreement with Company on any matter.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $82.18: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: RSI 48 mid-range, Bollinger mid-band. Prior stop was $76.04. Score 5.0/10, moderate confidence.
Take-profit target: $107.72 (+31.8% upside). Prior stop was $76.04. Stop-loss: $76.04.
Concentration risk — Pipeline: zumilokibart; Quality below floor (1.5 < 4.0).
Apogee Therapeutics, Inc. trades at a P/E of N/A (forward -15.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
23 analysts cover APGE with a consensus score of 4.3/5. Average price target: $120.
What does Apogee Therapeutics, Inc. do?Apogee Therapeutics is a clinical-stage biotech developing extended half-life antibodies for inflammatory and...
Apogee Therapeutics is a clinical-stage biotech developing extended half-life antibodies for inflammatory and immunology conditions. Lead program zumilokibart (APG777, anti-IL13) completed Phase 2b Part A for atopic dermatitis with positive results and is pursuing Phase 3 initiation in 2H 2026; additional programs APG808 (anti-IL4Rα), APG279, and APG273 are in Phase 1–2.